A 12-Month, Multicenter, Open-Label Extension Study (F202) to Evaluate the Long-term Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia

Trial Profile

A 12-Month, Multicenter, Open-Label Extension Study (F202) to Evaluate the Long-term Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Cyclobenzaprine (Primary)
  • Indications Fibromyalgia
  • Focus Adverse reactions
  • Acronyms BESTFIT-OLE
  • Sponsors Tonix Pharmaceuticals Inc
  • Most Recent Events

    • 23 Oct 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 08 Jan 2014 New trial record
    • 10 Dec 2013 Tonix Pharmaceuticals announced the enrolment of completers from the BESTFIT trial into a 12-month open-label extension study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top